MOESM8 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Additional file 8: Table S7. Functions of protein targets of treatment termination-associated antibodies. Functional analysis of protein targets for top 15 DE toxicity-associated antibodies for each of the anti-CTLA-4, anti-PD-1, and combination treatment groups. Associations of each antibody target with immune toxicity are given, based on literature findings

MOESM7 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Additional file 7: Table S6. Pathway analysis of protein targets of toxicity-associated antibodies. Lists of functional pathways (derived from WikiPathways; http://www.wikipathways.org/ ) enriched for protein targets of filtered toxicity-associated antibodies from anti-CTLA-4, anti-PD-1, or combination treatment groups

MOESM2 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Additional file 2: Table S2. Patient characteristics for reproducibility cohort (n = 10). Summary of clinical features from independent group of 10 melanoma patients treated with anti-CTLA-4 (n = 3), anti-PD-1 (n = 3), or combined anti-CTLA-4/anti-PD-1 (n = 4), and from whom serum samples were used to assess assay reproducibility. LDH, lactate dehydrogenase; POD, progression of disease; SD, stable disease; PR, partial response; CR, complete response; UNC, unclassified

MOESM8 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Additional file 8: Table S7. Functions of protein targets of treatment termination-associated antibodies. Functional analysis of protein targets for top 15 DE toxicity-associated antibodies for each of the anti-CTLA-4, anti-PD-1, and combination treatment groups. Associations of each antibody target with immune toxicity are given, based on literature findings

MOESM3 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Additional file 3: Figure S1. Pre- vs. post-anti-CTLA-4 treatment reproducibility (n = 39). (A) Correlation plot of global antibody profiles (array probe intensities) for pre- and postCTLA-4 treatment samples from patient 09-035. (B) Summary of correlation (r2) values for antibody profiles, including mean and standard deviation, between pre- and postanti-CTLA-4 treatment samples (n = 39 pairs)

MOESM1 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Additional file 1: Table S1. Detectable fold-changes (FC) at 80% power between toxicity groups for the three treatments. Power calculations for comparison of antibody levels between no/mild versus severe toxicity for the three ICI treatments

MOESM5 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Additional file 5: Table S4. Summary of toxicity- and termination-associated antibodies. Numbers of differentially expressed (DE), strongly differentially expressed (strong DE), filtered and curated antibodies are shown for comparisons of none/mild vs. severe toxicity, across three different treatment groups (anti-CTLA-4, anti-PD-1, and combination)

Additional file 1: of An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Cancer Immunotherapy Guidelines- Cutaneous melanoma version 2.0 Task Force Roster. (DOCX 13 kb

Additional file 3: of An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Cancer Immunotherapy Guidelines (Melanoma). (DOCX 145 kb